Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2252 Target Snapshot

Dipeptidyl peptidase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
987Compounds
97Assays
1Approved Drugs
2,322.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Dipeptidyl peptidase 1 shows late clinical disease relevance led by Bronchiectasis. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P53634. Start with Bronchiectasis, then reuse UniProt P53634 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Bronchiectasis, then reuse UniProt P53634 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Bronchiectasis

Dipeptidyl peptidase 1 shows late clinical disease relevance led by Bronchiectasis. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Bronchiectasis because it currently carries late clinical support. Linked drugs include BRENSOCATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dipeptidyl peptidase 1 as ChEMBL target CHEMBL2252, mapped to UniProt P53634. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dipeptidyl peptidase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2252
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P53634
Dipeptidyl peptidase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dipeptidyl peptidase 1 is the right protein anchor across sources, using UniProt P53634 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Bronchiectasis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDipeptidyl peptidase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP53634
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDipeptidyl peptidase 1
UniProt AccessionP53634
Component TypeProtein
Sequence Length463 aa

Dipeptidyl peptidase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Dipeptidyl peptidase 1, mapped to UniProt P53634. Sequence length is 463 aa.

Mapped IDP53634
Review nameDipeptidyl peptidase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Dipeptidyl peptidase 1 shows late clinical disease relevance led by Bronchiectasis. 4 more disease programs remain visible in the same review block.

Late clinical Phase III
Bronchiectasis
1 linked drug · 1 direct · 1 efficacy
Linked drugBRENSOCATIB
Late clinical Phase III
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugBRENSOCATIB
Clinical signal Phase II
cystic fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugBRENSOCATIB
Clinical signal Phase I
kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBRENSOCATIB
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBRENSOCATIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Bronchiectasis because it currently carries late clinical support. Linked drugs include BRENSOCATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseBronchiectasis
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
3
Phase III
Assay Mix

Activity Type Distribution

IC502,288.0
KI31.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5764453 9.7 IC50 0.2 Preclinical
CHEMBL3936580 9.6 IC50 0.2512 Preclinical
CHEMBL1079888 9.52 IC50 0.3 Preclinical
CHEMBL5897422 9.52 IC50 0.3 Preclinical
CHEMBL4561264 9.4 IC50 0.3981 Preclinical
CHEMBL5988711 9.4 IC50 0.4 Preclinical
CHEMBL5821570 9.3 IC50 0.5 Preclinical
CHEMBL5842574 9.3 IC50 0.5 Preclinical
CHEMBL5873696 9.3 IC50 0.5 Preclinical
CHEMBL5993798 9.3 IC50 0.5 Preclinical
Distribution

pChEMBL Value Distribution

13
5.0
42
5.5
76
6.0
222
6.5
352
7.0
533
7.5
567
8.0
195
8.5
81
9.0
6
9.5
pChEMBL
Assay Landscape

Assay Landscape

97
Total Assays
977
Tested Compounds
2
Assay Types
Binding — 96 assays, 977 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 64 853 7.8
cell-based format 25 123 7.0
assay format 7 1 6.9
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine